ABSTRACT We have selected a thioguanine-resistant lymphoblastoid cell line (LTR228) that forms human-human hybrids with high efficiency. Fusions with peripheral B cells consistently yield one colony per 105 cells plated. To produce antitetanus monoclonal antibodies, we withdrew blood from persons who had recently received booster injections of tetanus toxoid. T cells were separated from peripheral mononuclear cells by 2-aminoethylisothiouronium bromide-induced rosette formation, given 1,500 rads (1 rad = 0.01 gray), and cultured in a 1:1 ratio with nonrosetting cells. (6, 7) , and fusion with transformed lymphoblastoid cell lines (8, 9), or combinations of the above (10, 11) .
tetraploid amounts of DNA. From hybridomas grown in 5-liter spinner flasks, milligram quantities of the IgG,K antibody were purified by staphylococcus protein A affinity chromatography. Specific antibody from hybridoma cultures protected mice injected with 1,000 times the LD50 of tetanus toxin. Our cell line and associated techniques should permit the production of therapeutically important human monoclonal antibodies.
Many attempts to produce human monoclonal antibodies have been made since the early mouse hybridoma work of Kohler and Milstein (1) . Initial reports of successful fusions of human B cells and the U266 myeloma line (2) have not been confirmed in other laboratories. Problems with mycoplasma contamination of parent lines, suitable pre-fusion preparation of B cells, hybrid stability, and quantity of secreted monoclonal antibody have hampered most efforts with other human myeloma lines (3) . Other approaches have also met with limited success. These have included mouse plasmacytoma by human B-cell hybridization (4, 5) , direct Epstein-Barr virus (EBV) transformation of human B cells (6, 7) , and fusion with transformed lymphoblastoid cell lines (8, 9) , or combinations of the above (10, 11) .
We have developed an EBV-positive splenic lymphoblastoid cell line, LTR228 , that forms stable human-human hybridomas with high efficiency. Here we describe the production and characterization of antitetanus human monoclonal antibodies.
MATERIALS AND METHODS Cell Line. LTR228 is a lymphoblastoid cell line that originated in spleen cell culture (12) . We selected a spontaneous 6-thioguanine (20 ,g/ml)-resistant mutant for its high fusing capacity. Our line is mycoplasma-free and doubles every 16 hr when grown in Iscove's Dulbecco's minimal essential medium (DME medium) (GIBCO) with 15% fetal calf serum. LTR228 has a typical lymphoblastoid nuclear EBV nuclear antigen staining pattern.
Preparation of B Cells. Volunteers were vaccinated intramuscularly with tetanus toxoid (Wyeth, Philadelphia). Peripheral blood (80 ml) was drawn in heparin 9 days after vaccination. Lymphocytes were separated by Ficoll-Hypaque density gradient centrifugation. The lymphocytes were washed twice in Hanks' balanced salt solution and the T cells formed rosettes with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes as described (13) . The rosetted T cells (6 X 106) were exposed to 1,500 rads (1 rad = 0.01 gray) in a Gammacell 40 gamma-irradiator (Atomic Energy of Canada) and subsequently mixed with 6 x 106 nonrosetting B cells. The mixed cells were cultured at a density of 106 per ml in Iscove's DME medium/ 15% fetal calf serum/1% pokeweed mitogen (GIBCO). After 3 days the cells were again separated by Ficoll-Hypaque to obtain a population of primarily B-cell blasts. Preliminary experiments showed that B-cell blasts fused better than unstimulated lymphocytes. The irradiated rosette-forming T cells gave much less suppression than unfractionated lymphocytes.
Fusion Protocol. Cells were combined and fused according to the protocol of Brahe and Serra (14) with slight modification. Cells were fused with 40% polyethylene glycol 4,000 (BDH)/ 10%0 dimethylsulfoxide/poly(L-Arg) ( For soft agar cloning, 1,000 cells in 1 ml of 0.33% SeaPlaque agarose (FMC,. Rockland, ME), made in Iscove's DME medium/20% fetal calf serum, were placed over a bed of 4 ml of SeaKem agarose (04%) in 60-mm culture dishes (Falcon).
To select for a nonproducer parent cell line or for high-producer hybrids a reverse-plaque technique was used. Protein Acoated sheep erythrocytes (1.0%) were added to the upper layer of soft agar according to the method of Gronowicz et al. (19) . Clones secreting more antitetanus Ig had the largest plaques. A subclone of LTR228 secreting no Ig made no plaques. Table 1 We initially cloned the antitetanus cells by limiting dilution and in soft agar. Well El produced the greatest number of antitetanus-positive clones, and we selected these cells for further study. Sublines were recloned by limiting dilution, cell sorter, and soft agar methods. All subsequent clones, about 200, have continued to produce antitetanus antibody.
RESULTS
Morphological Characteristics of, Human Hybridomas. By light microscopy-the hybrids appeared to be larger than LTR228. However, scanning electron microscopy studies (Fig. 1) did not confirm this difference.
Although the hybridomas secrete up to 5 A.g of specific antibody per ml, transmission electron microscopy shows both hybrids and the parent LTR228 to have very little rough en- (20) .
-Growth Characteristics of Human Hybridomas. The hybridomas double every 25-28 hr as compared to every 16 hr for the parent (Fig. 2) . They can easily be, adapted to growth in serum-free Iscove's medium supplemented with bovine serum albumin (700 ,ug/ml)/transferrin (10 ,g/ml)/insulin (0.2 unit/ ml). Under such conditions, the time required for hybrid cultures to reach confluence is 30% longer than in Iscove's DME medium/15% fetal calf serum.
Stability of Human Hybridomas. After two rounds of cloning, all sublines continue to secrete antitetanus antibody. Eight months in culture and expansion of cells in 4-liter vessels has not altered the secretion of specific antibody. Furthermore, cell sorter histograms showed 12 representative clones all to have nearly tetraploid DNA levels (Fig. 3) . Chromosome studies yield similar conclusions (Fig. 4) Fig. 7 shows plots of forward-angle light scattering (cell size) vs. logarithm fluorescence for surface Igs, DR, Leu-10 (a D-region-associated antigen) and B1 (a B-cell differentiation antigen) (21) . When compared with LTR228, the hybrids express less BL, more DR, more Leu-10, and approximately equivalent amounts of surface Ig. The parent LTR228 also stained with several anti-y reagents, despite the fact that IgM was the only Ig internally labeled and immunoprecipitated (see Fig. 6 ). The plots also show the cloned hybrids to be more heterogeneous in size than the parent cell lines.
-Hybrids-cloned by the cell sorter for increased or decreased expression of B1, DR, or Leu-10 antigens failed to secrete a level of Ig different from the parent (data not shown). Monoclonal Antibody Protects Mice from Lethal Tetanus Toxin Injection. Outbred Swiss-Webster mice (20 g) were injected intraperitoneally (0.5 ml) with various-doses of tetanus toxin mixed with serum-free medium conditioned by either hybridoma or LTR228 cells. Doses of toxin were 1-1,000 times the LD' . Results in Table2 show that the monoclonal antibody is protective in vivo against the lethal effects of tetanus toxin. DISCUSSION Several workers have shown that EBV-infected B-cell lines can be used to produce human monoclonal antibodies (8, 9, 11, 22) . Although human myeloma lines are available,-they have not been as useful in producing hybridomas as EBV-infected B-cell lines. Even under optimal conditions, human myeloma cell lines fuse with-lower frequency, grow more slowly, and are unstable. producers of Ig (unpublished data).
We have developed an EBV-infected B-cell line that greatly facilitates production of human hybridomas. By using-this line we have produced and purified-a specific human monoclonal antibody, IgG (Fig. 7) . However, the ease with which hybrids of LTR228 clone and form reverse plaques has permitted us to select for high-secreting clones approaching the production of mouse hybridomas.
One of the antitetanus hybrids has been adapted to growth Results indicate surviving mice (at day 4)/total mice injected.
* 1 unit = LD50.. to.5 ml of-spent medium was mixed with tetanus toxin and injected intraperitoneally.
in nude mice (unpublished results). Inoculation of 107 cells subcutaneously produces tumors within 3-4 weeks; After removal from the mouse and subsequent in vitro culture, this clone has permitted the production of ascites with a high titer of human monoclonal antibody. When nude mice were injected with adapted cells (2 x 107), ascites containing 0.5 mg of specific antibody per ml formed within 2 weeks. Production of purified antigen-specific monoclonal antibody in milligram quantities will make it possible to use human antibodies when murine products are either ineffective or immunogenic. Passively administered human antibodies can be used to treat hemolytic disease of the newborn (Rh), tetanus, rabies, hepatitis B, Gram-negative sepsis, and snakebite. Future uses may include radioimaging with tracer-labeled antibodies, toxin-antibody conjugates to modulate immunological diseases, and antibodies to eliminate toxins or drugs. Human proteins should be less antigenic and, in some cases, more specific, and they should have longer in vivo half-lives because of the correct species-specific carbohydrate side chains and Fc sequences. Human Fc sequences may also augment the bioactivity of antibodies binding to macrophages or lymphocytes in vivo.
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